Therapeutics biotech company developing proprietary drug delivery platform technology.
Location: United States, Massachusetts, Cambridge
Total raised: $265.5M
Investors 3
Funding Rounds 3
| Date | Series | Amount | Investors |
| 08.05.2021 | - | $112.5M | - |
| 09.12.2020 | Series A | $45M | RA Capital... |
| - | - | $108M | - |
Mentions in press and media 18
| Date | Title | Description |
| 12.05.2026 | AstronauTx builds executive team with appointment of experienced clinical development leader Michelle Mellion, MD as Chief Medical Officer | London, UK, 12 May 2026 – AstronauTx Ltd (“AstronauTx”), a biotechnology company developing therapeutics to treat Alzheimer’s Disease and other neurological disorders by improving sleep architecture, announces the appointments of Dr. Michel... |
| 13.03.2024 | PepGen to Participate in Upcoming Investor Conferences | - |
| 13.03.2024 | PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy | - |
| 06.03.2024 | PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments | - |
| 07.02.2024 | PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock | - |
| 10.08.2021 | Digital health news, funding roundup in the prior week; August 9 | PepGen raised $112.5M; Lucid Lane landed $16M; Kensho Health secured $3.5M; DynamiCare Health picks T-knife Therapeutics: T-knife Therapeutics is a Berlin-based, pre-clinical-stage biopharmaceutical company developing tumor-specific T cell ... |
| 05.08.2021 | Back from the dead, Brandless moves into the creator economy and e-commerce rollups | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content The art of swapping cars—for art From Polestar Brandless, an e-commerce company that... |
| 05.08.2021 | PepGen Announces Closing of $112.5 Million Crossover Financing to Advance Transformative Therapies for Neuromuscular Diseases | BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- PepGen, Inc., a company developing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced the closing of an oversubscribed $112.5 million crossover fina... |
| 05.08.2021 | Back from the dead, Brandless moves into the creator economy and e-commerce rollups | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Brandless, an e-commerce company that once sold sustainable household goods for about $3 a piece,... |
| 05.08.2021 | PepGen raises $113M to challenge Sarepta in DMD, build neuromuscular and neurologic pipeline Age-Appropriate Formulation Development for Pediatric Trials-Challenges and Considerations | PepGen has raised $112.5 million to take a treatment for Duchenne muscular dystrophy (DMD) into the clinic early next year. The crossover round positions PepGen to start showing whether its technique for getting more oligonucleotides into c... |
Show more